Analytical Data
-
Gene name
SLC4A1
- Application
-
Alternative Names
AE1; DI; EPB3
-
Species
Human
-
Source
HEK293
-
Tag
His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P02730-1
-
Expression Region
M1-V911
-
Protein Length
Full Length of Isoform-1
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SLC4A1, also known as the anion exchanger 1 (AE1), is a critical integral membrane protein primarily expressed in erythrocytes and renal tubules, where it plays a key role in maintaining acid-base balance by facilitating the exchange of bicarbonate (HCO3-) and chloride (Cl-) ions. Its dysfunction is linked to various hematological disorders, including hereditary spherocytosis and distal renal tubular acidosis, highlighting its importance in physiological processes. The study of SLC4A1 recombinant protein has garnered significant interest due to its potential implications in understanding these diseases and developing therapeutic strategies. Recombinant SLC4A1 allows for detailed examination of its structure-function relationships, ion transport mechanisms, and interactions with other cellular components. Advances in recombinant DNA technology have made it possible to express SLC4A1 in heterologous systems, enabling researchers to investigate its properties in isolation. This research not only enhances our comprehension of the protein's role in normal and pathological states but also paves the way for potential drug development aimed at modulating its function. Understanding the molecular basis of SLC4A1's operation could lead to novel interventions for conditions related to acid-base imbalances and red blood cell disorders, thereby addressing significant health challenges.
